News & Views | Published:

Glycolysis and EZH2 boost T cell weaponry against tumors

Nature Immunology volume 17, pages 4142 (2016) | Download Citation

Low availability of glucose in tumors negatively affects the activity of tumor-infiltrating T cells. Loss of T cell function under these conditions is mediated by the microRNAs miR-101 and miR-26a, which target expression of the methytransferase EZH2 and thereby diminish the expression of anti-tumor cytokines.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Cell 153, 1239–1251 (2013).

  2. 2.

    et al. Nat. Immunol. 14, 1064–1072 (2013).

  3. 3.

    et al. Nat. Immunol. 17, 95–103 (2016).

  4. 4.

    , , & Nat. Rev. Cancer 12, 298–306 (2012).

  5. 5.

    & Trends Immunol. 36, 257–264 (2015).

  6. 6.

    et al. Cell 162, 1229–1241 (2015).

  7. 7.

    et al. Cell 162, 1217–1228 (2015).

  8. 8.

    et al. Science 344, 641–645 (2014).

  9. 9.

    et al. Immunity 39, 819–832 (2013).

  10. 10.

    et al. J. Immunol. 192, 5012–5022 (2014).

  11. 11.

    et al. Nat. Immunol. 15, 1143–1151 (2014).

  12. 12.

    et al. Cancer Immunol. Res. 2, 800–811 (2014).

  13. 13.

    et al. Mol. Cancer 9, 108 (2010).

Download references

Author information

Affiliations

  1. Glenn R. Bantug and Christoph Hess are in the Department of Biomedicine, University of Basel, Basel, Switzerland.

    • Glenn R Bantug
    •  & Christoph Hess

Authors

  1. Search for Glenn R Bantug in:

  2. Search for Christoph Hess in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Christoph Hess.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ni.3346

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing